Cytokinetics CYTK Common stock issuance for private placement
Common stock issuance for private placement at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfPrivatePlacement.
The official record: Cytokinetics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's common stock issuance for private placement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's common stock issuance for private placement?
- Cytokinetics (CYTK) reported common stock issuance for private placement of $0 in Q4 2025.
- How has Cytokinetics's common stock issuance for private placement changed year-over-year?
- Cytokinetics's common stock issuance for private placement decreased by 100.0% year-over-year, from $12.5M to $0.
- What does common stock issuance for private placement mean?
- Cash raised by selling shares to private investors.
- How do you interpret common stock issuance for private placement?
- Higher inflows indicate strong investor confidence and successful capital raising, while lower inflows may suggest difficulty in securing private funding.
- How does common stock issuance for private placement compare across companies?
- A standard practice for pre-revenue or clinical-stage biotech companies to extend their cash runway.